研究单位：[1]Sun Yat-sen University[2]Beijing Tongren Hospital, Capital Medical University,Beijing,China[3]Peking Union Medical College Hospital,Beijing,China[4]The Second Hospital of Dalian Medical University,Dalian,China[5]Sun Yat-Sen University Cancer Center,Guangzhou,China[6]The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University,Guangzhou,China[7]Jiangxi Cancer Hospital,Nanchang,China
研究目的：
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy in combination with tislelizumab and mitoxantrone hydrochloride liposome combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）
